Notícias

Best Buy had a strong first quarter, and second-quarter earnings will have a tough act to follow in the face of persistent inflation.

Investing.com -- CrowdStrike Holdings Inc. shares climbed more than 9% in after-hours trading Wednesday following stronger-than-expected quarterly results and an increased full-year forecast.

Investing.com -- Salesforce Inc. (NYSE: CRM) crushed Wall Street’s second-quarter expectations, driven by an explosive surge in AI demand and expanding margins that sent shares climbing 11% after hours.

Bloomberg's Hannah Miller joins Dani Burger on "Bloomberg Deals." Paramount has acknowledged that it's considering a wide range of options to settle lawsuits challenging its $110 billion acquisition of Warner Bros. Discovery.

Identity management company Okta (NASDAQ:OKTA) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 10.6% year on year to $805 million. Guidance for next quarter’s revenue was better than expected at $815 million at the midpoint, 0.9% above analysts’ estimates. Its non-GAAP profit of $1.05 per share was 8.9% above analysts’ consensus estimates.

Both discount retailers are expected to post solid growth, but their valuation, stock performance, and shareholder-return profiles offer investors two different setups heading into Q2 earnings.

Cybersecurity platform provider CrowdStrike (NASDAQ:CRWD) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 25.8% year on year to $1.47 billion. Guidance for next quarter’s revenue was better than expected at $1.53 billion at the midpoint, 0.7% above analysts’ estimates. Its non-GAAP profit of $0.31 per share was 6.4% above analysts’ consensus estimates.

The software company reported $11.35 billion in second-quarter revenue and now expects $46.1 billion to $46.4 billion for the full year

The cybersecurity company is benefiting from AI adoption that is driving demand for security products.

CRM software giant Salesforce (NYSE:CRM) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 10.8% year on year to $11.35 billion. The company expects next quarter’s revenue to be around $11.46 billion, close to analysts’ estimates. Its non-GAAP profit of $5.90 per share was 80.4% above analysts’ consensus estimates.

Salesforce (CRM) reported second quarter results on Wednesday after the closing bell. Adjusted earnings per share (EPS) came in at $5.90, while revenue came in at $11.35 billion (compared to analyst estimates of $11.32 billion). Third quarter revenue guidance came in at $11.42–11.5 billion. Yahoo Finance's Josh Lipton takes a closer look at the breaking numbers.

Salesforce Inc (NYSE:CRM, XETRA:FOO) shares rose 11.4% after the bell on Wednesday after the enterprise software company posted second-quarter results that topped Wall Street estimates and raised its full-year guidance. The company reported fiscal 2027 second-quarter revenue of $11.3 billion,...

Hybrid multicloud computing company Nutanix (NASDAQ:NTNX) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 15.9% year on year to $757.1 million. Guidance for next quarter’s revenue was better than expected at $760 million at the midpoint, 0.7% above analysts’ estimates. Its non-GAAP profit of $0.60 per share was 23.6% above analysts’ consensus estimates.

SLYG charges lower fees, but RZG has delivered a higher one-year return.

Nvidia stock was quiet Wednesday ahead of the AI chipmaker's fiscal second-quarter earnings report, due after the market close.

The $330 target promises a dramatic recovery, but Oracle's negative free cash flow keeps the burden of proof unusually high.

Amazon was pinpointed as a major growth candidate by several hedge funds last quarter.

Both NVIDIA and Broadcom just posted record quarters riding the same AI infrastructure wave, but for retirement investors, one of these chip giants fits the portfolio and one quietly works against it.

The “Big Short” investor says his theoretical value for Nvidia is “much lower than today’s market value” as he sees a short run for its monopoly power.

On August 10, 2026, Teledyne Technologies Incorporated (NYSE:TDY) agreed to acquire Varex Imaging for $18.90 a share in an all-cash deal valued at about $1.1 billion. It sent Varex Imaging Corporation (NASDAQ:VREX) shares up nearly 50% before the opening bell. Why This Matters Teledyne is paying a large premium for a smaller X-ray components maker […]

Navitas’ Claros acquisition could reshape its growth prospects, giving investors another factor to weigh as they assess the stock.

The drugmaker's stock is on a tear, but for investors arriving now, the real question is whether the business can outrun its own premium price.

The company is firing on all cylinders.

Broadcom stock gained on news of fresh $60 billion debt talks with Blackstone and Apollo Global Management.

The market is offering a creative software giant at a steep discount, but the price tag comes with a question about the company's next chapter.

IBM has introduced the first dual‑architecture mainframe processor in collaboration with Arm Holdings

SCHD has delivered solid income and returns in 2025, but a lesser-known international ETF has quietly outpaced its benchmark while nearly doubling SCHD's yield, and the strategy behind it challenges everything most investors assume about covered call funds.

SPGM has delivered slightly higher one- and five-year returns, while VT offers lower costs and deeper diversification.

Super Micro Computer (NasdaqGS:SMCI) is expanding its AI infrastructure partnership with Cisco and NVIDIA to deliver integrated rack scale solutions for neocloud and sovereign cloud customers. The collaboration incorporates Supermicro high density, liquid cooled and air cooled servers into Cisco's Secure AI Factory infrastructure for next generation AI data centers. The joint offering is aimed at enterprises and cloud providers that want to deploy efficient and secure AI workloads at...

Amgen (NasdaqGS:AMGN) has elected to terminate its research collaboration and license agreement with TScan Therapeutics focused on Crohn's disease target discovery. The decision ends Amgen's exclusive effort with TScan to identify and develop T-cell antigen targets for Crohn's disease. This change may affect Amgen's research pipeline in inflammatory bowel disease and influence its future approach to biotech partnerships. For broader context on the sector, consider exploring other...